Podcasts about Ashish

Every two years, Ligonier Ministries and Lifeway Research release The State of Theology—a massive survey that reveals what Americans (including evangelicals) actually believe about God, the Bible, Jesus, and culture. The 2025 report is out, and some of the numbers are… surprising. In this episode of Thinking Christian, Dr. James Spencer is joined by longtime friend and theologian Dr. Ashish Varmafor a wide-ranging conversation about what the data shows—and what it doesn’t show—about the theological landscape among evangelicals today. Rather than panicking over headline-grabbing statistics, James and Ashish analyze the deeper trends beneath the numbers. Together they explore: Why young evangelicals differ sharply from older generations on questions like the Bible’s literal truth and whether science conflicts with Scripture. Why nearly all evangelicals still say the Bible is their highest authority, even when their answers elsewhere seem to contradict that claim. How access to information, cultural context, and community shape belief—for better or worse. The surprising power of church attendance and affiliation in reinforcing core doctrines (and where that influence seems to break down). Why political theology may be quietly distorting how Christians answer moral questions—especially younger believers. Which troubling survey results actually matter—and which ones may simply reflect fuzzy categories or ambiguous wording. How churches should respond: not with panic or doctrinal hammering, but with thoughtful discipleship, richer community life, and deeper formation. James and Ashish also dive into the complexities of interpreting theological surveys at all—how beliefs are shaped by cultural habitus, how people understand (or misunderstand) terms like myth, literal, or love, and why surveys often reveal more about our formation than our formal theology. If you’re curious about what evangelicals really believe—and what the church can do about it—this episode offers a hopeful, nuanced, and deeply thoughtful guide through the data. Subscribe to our YouTube channel

In this episode, we take a deep dive into the global climate-tech ecosystem, with a focus on how innovation can be translated into deployment, and what needs to be done to scale renewable integration. We are joined by Ashish Khanna, Director General, International Solar Alliance, to explore where do we lack when it comes to accelerating climate-tech innovation. He says it is important to see the glass half full and India has an immense potential, it can become a hotbed for innovation. Building on the momentum created by ENTICE, this episode explores how ideas become deployable solutions - through financing, policy support, and real-world testing. Tune in!

Hey everyone, December started strong and does NOT want to slow down!? OpenAI showed us their response to the Code Red and it's GPT 5.2, which doesn't feel like a .1 upgrade! We got it literally as breaking news at the end of the show, and oh boy! The new kind of LLMs is here. GPT, then Gemini, then Opus and now GPT again... Who else feels like we're on a trippy AI rolercoaster? Just me?

Guests Dr. Andrea Necchi, Dr. Ashish Kamat and host Dr. Davide Soldato discuss JCO article "End Points for the Next-Generation Bladder-Sparing Perioperative Trials for Patients With Muscle-Invasive Bladder Cancer," focusing on the evolving treatment landscape of MIBC (muscle-invasive bladder cancer) and the need to properly design novel trials investigating non-operative management while including the incorporation of biomarkers and patient perspectives in clinical trials. TRANSCRIPT The disclosures for guests on this podcast can be found in the show notes. Dr. Davide Soldato: Hello and welcome to JCO After Hours, the podcast where we sit down with authors from some of the latest articles published in the Journal of Clinical Oncology. I am your host, Dr. Davide Soldato, medical oncologist at Ospedale San Martino in Genoa, Italy. Today we are joined by JCO authors Andrea Necchi, Associate Professor of Medical Oncology at University San Raffaele and Medical Oncology at Ospedale San Raffaele in Milan, Italy, and Ashish Kamat, Professor of Urologic Oncology and Cancer Research at University of Texas MD Anderson Cancer Center. Both Professor Necchi and Professor Kamat are internationally recognized experts in the field of genitourinary malignancy and particularly in bladder cancer. Today we will be discussing the article titled "Endpoints for the Next Generation Bladder-Sparing Perioperative Trials for Patients with Muscle-Invasive Bladder Cancer." So thank you for speaking with us, Professor Necchi and Professor Kamat. Dr. Andrea Necchi: Thank you, Davide, and thank you JCO for the opportunity. Dr. Ashish Kamat: Yeah, absolutely. It is a great honor and privilege to be discussing this very important article with you. So thank you for the invitation. Dr. Davide Soldato: The article that you just published in JCO reports the results of a consensus meeting that was held among experts in the field of genitourinary malignancy and particularly for bladder cancer. So the objective was really to define endpoints for a novel generation of trials among patients diagnosed with muscle-invasive bladder cancer. So my first question would be: what is the change in clinical practice and in clinical evidence that we have right now that prompted the start of such consensus in 2025? Dr. Andrea Necchi: So, we are living so many changes in the treatment paradigm of patients with muscle-invasive bladder cancer. In general, patients diagnosed with bladder cancer or urothelial cancer today, thanks to the advent of immunotherapy or immunotherapy combinations, and today thanks to the advent of novel antibody-drug conjugates like enfortumab vedotin in combination with immunotherapy that are actually changing the landscape of treatment of patients with metastatic disease and also are entering quite fast into the treatment paradigm of patients with organ-confined disease with a lot of clinical trials testing these combination therapies, neoadjuvantly or adjuvantly, before or after radical cystectomy. Having said that, by potentiating the efficacy of systemic therapy, an increasing number of patients that receive neoadjuvant therapy of any kind, at a certain point in time, result to have achieved a deep response to systemic therapy, evaluated radiologically with conventional imaging, CT scan or MRI, or with cystoscopy or with other urology-based techniques, urinary cytology, and so. And based on the fact that they achieve a complete response, so no residual viable disease after systemic therapy, they raise concern about the fact that they have to undergo surgery like radical cystectomy that is quite impactful for their quality of life and for the future of their lives after the surgery. So the point that the patients are raising, and the patients are raising this point, is primarily due to the efficacy of systemic therapy. And we have seen so many cases fortunately achieving a deep response. So the question about what to do with the patient that at a certain point, at the start with the commitment to radical cystectomy, but at a certain point in time change their mind towards something else if possible, depending on the fact that they have achieved a deep response, is something that is a question and is a need to which we have to provide data, information, and guidance in general to the patients. Dr. Davide Soldato: If we look at the population that the recommendations were formulated for, we are mainly speaking about patients who would be fit for cystectomy, and this is a very distinct population compared to those who are not fit for cystectomy, both from a medical oncology point of view but also from a urologic point of view in terms of surgery. So, can you explain a little bit to our listeners why you think that this distinction is critical and why you developed this recommendation especially for this population? Dr. Ashish Kamat: That is a very important distinction that you made. To build upon what Professor Necchi mentioned earlier, this question that we get from patients after neoadjuvant therapy or systemic therapy is not a new question. It has been something that they have been asking us for the last 20 or 30 years. "Do I really need to have my bladder taken out?" And patients who are especially not fit for surgery will sometimes say, "Do I need to have my bladder taken out? And if I cannot have my bladder taken out, am I going to just not have anything done?" Because the eligibility for radical cystectomy is also a moving target. Over the years with improvement in surgical technique, improvement in perioperative therapy, ERAS protocols, et cetera, it is really unusual for us to deny a patient the opportunity to have major surgery unless clearly they have very significant comorbid conditions. So I think this endeavor is more broadly encompassing of the patient population than what was evident in previous years. And I really want to give a shout out to Professor Necchi because what we did was, as part of the International Bladder Cancer Group and Professor Necchi is an integral part of the scientific advisory board, we broached this topic broadly during one of our discussions. And of course, Andrea always does this, he picks on a topic and then he says, "Okay, we need to discuss this really in detail," put together a multinational, multicenter collaborative group, but the driving force was our patients. Because our patients are constantly asking, "Do I need to lose my organ? Do I need to have radiation therapy?" which again, also, has a lot of side effects. So this was really to answer the question in today's day and age as to do we need to do local consolidation, and if so, in what way? It is not a new question, but we have newer therapies, newer technology, and better ways to answer this. So it is a much needed question that needs to be answered. And I think the distinction between non-surgical candidates and surgical candidates is a little bit blurred in today's day and age. Dr. Davide Soldato: What about the eligibility, for example, for cisplatin-based chemotherapy? Because I think that that is a very fundamental part of this type of strategy that we apply to patients with muscle-invasive bladder cancer. So we know that there are some caveats for proposing such treatment. And also this population was specifically defined inside this recommendation. Dr. Andrea Necchi: I think that the focus of our work is just to analyze what is happening after any type of systemic therapy the patient may get neoadjuvantly. So it is not actually a question of treatment eligibility or including cisplatin eligibility. This is an old question of today's practice and clinical trials. But regardless of what the patient received neoadjuvantly, the point that we have addressed in our consensus meeting was what to do next as a further step after systemic therapy or not. So basically we are- the consensus guidance includes all-comers, so patients to get any type of systemic therapy. So really non-selected based on specific features that determine a special eligibility to a special or a particular therapy. But an all-comer approach is always the winning approach for the translation to be in practice, an all-comer approach just focusing on what has happened after treatment and that we are assessing by the use of conventional imaging, MRI or CT, cystoscopy, urinary cytology, and trying to merge all together this information, all these features in a unique, shared, reliable definition of clinical complete response that could be used as a biomarker for the selection of newer therapies instead of pathological response that has been historically used, and maybe surrogate for the outcome, the long-term outcome and survival of these patients. Dr. Davide Soldato: A very specific point of the consensus was actually the definition of clinical complete response. As you were saying, this is actually a combination of several parameters including urinary cytology, the use of cross-sectional imaging, for example CT scan, but also the evaluation in cystoscopy of the bladder. Do you foresee any potential problems when applying this type of recommendation, not inside clinical trials, but in the context of routine clinical practice? Dr. Ashish Kamat: Absolutely. And that was the whole reason we had this consensus meeting. What happens nowadays in daily practice, and we see this every day at our center, we see patients referred to us. This definition or this sort of attempt to define clinical complete response is an ongoing issue. And urologists, medical oncologists, radiation oncologists are always looking to see, does my patient have a complete response? That definition and those paradigms have changed and evolved over the years. The FDA had a workshop many years ago looking at this very question. And it was to address the proposal that complete clinical response, which is a clinical definition, a clinical state, does this correlate with pathologic response? And with the technology and the systemic therapies we had then, the answer was 'no'. In fact, more patients got recurrent disease than did not get recurrent disease. And that is why, of course in the paper we mention the trials that looked at this question, the trials that evolved around this question. And I think the distinction between a clinical trial and daily practice is extremely important when we are looking at this definition per se. Because essentially what happens with this issue is that if the patient is not appropriately counseled, and if the physician does not do the appropriate clinical complete response assessment as Professor Necchi mentioned, right, cystoscopy, cytology, imaging, use of markers that are still in evolvement, we risk doing harm to the patient. So we caution in the paper too that this definition is not ready for prime time use. It is something that needs to be studied. It is a rigorous definition and currently we are recommending it for clinical trials. I am sure eventually it will trickle down into clinical practice, but that guidance was not the purpose of this consensus meeting. Dr. Davide Soldato: There are several parameters that are potentially evolving and could potentially enter inside of clinical practice. For example, you mentioned pelvic MRI and we have now very specific criteria, the VI-RADS criteria, we're able actually to diagnose and also to provide information. So along with these novel imaging techniques, we also know that there are novel biomarkers that could be explored, for example ctDNA and urinary DNA. So what I was wondering is, why were not these included inside the definition that you provide for clinical complete response? And do you think that, as we are designing these trials to potentially spare cystectomy for this patient, we should include these biomarkers very early so that we can actually provide better stratification for our patients and really propose this type of cystectomy-sparing strategy only to those where we are very confident that we have obtained a clinical complete response? Dr. Andrea Necchi: I would say you have just to wait. So a follow-up is ongoing and hard work is ongoing. At the time we met, at the time we established the meeting in mid-December last year, we had no information on the ctDNA data from major trials, with only a few exceptions. So we were just at the beginning of a story that was more than likely to change but still without numbers and without data from clinical trials. Now in just nine months or 10 months time, we have accumulated important data and newer data will be presented during just a few weeks and a few days regarding the ctDNA, circulating tumor DNA in particular, as a prognostic marker assessed baseline or assessed after neoadjuvant therapy. So the point is certainly well made and ctDNA is certainly well shaped to be incorporated in a future definition of clinical complete response. But you have to consider the fact that most of the data that we are accumulating related to ctDNA are about the post-cystectomy field or the metastatic field. So regarding neoadjuvant therapy, you know, we have neoadjuvant therapy in the context of bladder-sparing approach, basically we have no information. And the point that is emerging in our daily practice when using these biomarkers or in clinical trials, and the impression in general, is that it is a very strong biomarker associated with survival, but we absolutely do not know what is the performance of the test in the prediction of superficial bladder relapses, high-grade pTa relapse in the bladder that is left untouched in the patient. We are considering, and maybe it will be just a matter of further discussion, not just what is happening within the immediate endpoint of clinical CR, but also what is happening later with other survival endpoints. And for example, when looking at the type of events that we may see in this kind of bladder-sparing approaches, most of the events, also in the trials that have been published including the RETAIN study published in JCO, most of the events are related to superficial high-grade superficial non-muscle invasive relapses. So the ability to predict these types of events with ctDNA is completely unknown. Maybe, maybe other liquid biomarkers like urinary tumor DNA, utDNA, could be a bit better shaped in the prediction of this kind of events, you know. But we have still to build the story. So the question is good. The answer is yes, we will likely, more than likely incorporate liquid biomarkers in the definition, but we have to wait at least more data and more robust data in order to translate this information in routine practice, you know. Another consensus meeting is organized by IBCG and the same folks for November. This meeting will be primarily focused on the liquid biomarkers, the interpretation and use and approval and so of liquid biomarkers including bladder cancer. And we will likely be able to address all these, most of these open issues, so most of these points in the next meetings. Dr. Davide Soldato: In the consensus you say that probably clinical complete response is now ready to be included in early phase trials, so actually to test what is the efficacy of the regimens that is being evaluated inside of these trials. But you actually do very in-depth work of defining what are the most appropriate endpoints for later phase trials. So to be very specific, the phase three registrational trials that bring new regimens inside of this space. So I just wanted to hear a little bit about what was the definition for event-free survival, which you define as the most appropriate one for this type of trials. And as you were mentioning before, Professor Necchi, there is a very specific interest on the type of events that we observe, especially when we look at these superficial relapses inside of the bladder. So was this a very urgent matter of debate as we define which type of events should actually trigger event-free survival? And did you make a very thoughtful decision about why using this type of endpoint instead of others, for example metastasis-free survival? Dr. Ashish Kamat: Yeah, this was a matter of intense debate as you might imagine. And again, this is a moving target. So as Professor Necchi mentioned, we tend to partner with each other, our organizations, on having definitions of clinical complete response, biomarker, retreats, and then using that as a marker, and you might imagine this definition of what is appropriate event-free survival, what events matter to the patient, is something we have been talking about for two years. It was not just something that came up at the retreat. But at the retreat there was intense discussion. One of the things that we talked about was bladder-intact event-free survival because we are trying to spare the patient's bladder. And do we count bladder-intact event-free survival as something that is relevant? The patient advocates absolutely liked that, right? They wanted that. But then we also learned from some of the studies, for example from the RETAIN study, that the non-muscle invasive recurrences can actually lead to metastatic disease. It is not as benign when you have a patient with muscle-invasive bladder cancer that then develops a non-invasive tumor because maybe there is cancer growing underneath the surface that we don't detect when we look in the bladder. So a lot of those discussions were held, debated. It was a consensus. I have to say it was not 100% agreement on that particular definition, but it was broad consensus. And Andrea, do you want to clarify a little bit as to how we came about that consensus? Because I think this is a very important point we need to make. Dr. Andrea Necchi: We focused on a bit different definition of BI-EFS, Bladder-Intact Event-Free survival. Just stating EFS as an all-inclusive parameter including all type of high-grade relapse or progression or death that may happen to the patient. So that we were counting high-grade pTa, pT1, CIS relapses to the bladder and of course more deeper involvement in the muscle layer and so, and metastatic disease as a relapse. But the point is that as compared to the classical bladder-intact EFS definition of chemoradiation bladder-sparing approaches that is including muscle-invasive relapses only or death as events, we tried to be as inclusive as possible in order to be as much conservative as possible and to raise as higher the bar as possible for the success. And this is actually what the patients are asking us. So they are asking, "Okay, I can save my bladder, sparing radical cystectomy, but at which cost?" So in order to provide an answer, we have to be very, very cautious and be on the right shape, on the right position to say, "Okay, we have accomplished the most, the safest points, you know, by which you can proceed with the bladder-sparing." This is the first point. The other point is related to the MFS, metastasis-free survival that you have mentioned. For sure, it was recognized as a very important point for sure. But in the discussion was clear that our focus was in saving patients, curing the patient, and saving the bladder. Any single event, superficial event that may occur in the bladder-saving approaches of this kind may expose the patient to an extra risk of developing distant metastases, as it happened for example in the RETAIN study. So EFS defined as we have agreed and published, is actually a way of including or anticipating in a safest position the MFS. Because most or if not the entirety of the events of metastasis development in patients undergoing bladder-sparing after neoadjuvant systemic therapy were preceded by a superficial phase of disease relapse, you know. So I remember very, very few, or we can count just on the finger of one hand, the cases that have been reported in the literature developing de novo metastatic disease in the similar bladder-sparing approaches, in particular when using a maintenance immunotherapy strategy, you know, after they reach TURBT. So this is the reason why with all the limitation that Ashish has mentioned, with all the uncertainties that are still there, the nervousness that is still there, EFS, as defined in the protocol, as put in the paper, is to us at the moment is the safest way to use a primary endpoint in potentially registration trials of this kind with perioperative systemic therapy and response-adapted surgery. Dr. Ashish Kamat: And David, just to be absolutely clear for our listeners, right, so what was the event-free survival that we defined? Essentially it was a very inclusive definition. Event was defined as high-grade tumor persistence, recurrence, or progression during or after perioperative therapy, and receipt of any additional standard of care treatment including radical cystectomy, radiotherapy or even intravesical therapy. So this was done at the behest of our patient advocates because we really wanted to make a very robust definition that could be utilized appropriately as an adequate primary endpoint for both early and late phase bladder preservation trials. Dr. Davide Soldato: I think that it really highlights one of the points that I liked the most about this consensus is that it really incorporated the patient vision and a sort of shared decision making process when we are deciding how we want to design these trials that will explore this bladder-sparing surgery. And Professor Necchi mentioned something that I think will be also a very interesting question for trials that will be developed considering the activity of this combination that we are seeing right now, which is maintenance. Because right now our approach in the few cases where patients do not do any type of treatments after an induction with neoadjuvant treatments is basically represented by observation. So I was wondering if you think that the field will actually evolve to a sort of maintenance strategy even in patients that will achieve a complete clinical response? Dr. Andrea Necchi: We just mentioned briefly in the paper, this is a very important point that was touched during the discussion, and in particular was raised and discussed by FDA people participating in the meeting. And when looking at the data from the trials that were available and are still available thus far, we could provide a suggestion that maintenance immune therapy is the preferred approach in this kind of approach as it currently stands, as the data currently stand. Because the cleanest data towards the successful part of this journey is related to the studies that provided a kind of maintenance therapy, like the study with nivolumab or the RETAIN-2 study with maintenance immune therapy instead of RETAIN study that was just stopping treatment until surgery with MVAC chemotherapy. So in general the impression is that maintenance therapy may help in reducing the type of events, including the events that we incorporate in the EFS definition that we mentioned in the paper. The point that you mentioned is very important because on the other side we have a problem, a big problem of affordability and cost of the treatment. The de-escalation trials are an urgent need and represent a call for the studies. Unfortunately, as you mentioned, this is something that moves beyond the possibilities of this type of consensus because we don't have data and we have to accumulate data from clinical trials prior to saying, "Okay, certain patients could de-escalate therapy and stop therapy and some other not." So we are still at the very beginning. So we can do- we can discuss about this in the radical cystectomy paradigm but not in the bladder-sparing paradigm, you know. But this is for sure a point, a discussion point that will be taken, pretty well taken in one year or two year projection. Dr. Davide Soldato: I was wondering if in the consensus, considering that patient advocates and patient associations were also involved, did you decide to actually suggest the inclusion of patient-reported outcomes or the evaluation of shared decision-making in the development of this trial really as endpoints that should matter as much or as much as possible as event-free survival and clinical complete response? Dr. Ashish Kamat: Oh yeah, absolutely. We had patient advocates, we had the World Bladder Cancer Patient Coalition, Bladder Cancer Advocacy Network, patient representatives. And we always consider this. Shared decision-making is actually the impetus behind why these efforts have been launched, right? So it is the shared decision-making that is very, very important. It is the driving force behind what we do. And it is worth noting, for example, for the design of such studies, regulatory agencies consider response-based endpoints or overall survival as primary endpoints. But the patient advocates consider quality of life to be just as important, if not more important sometimes than overall survival numbers. Because patient advocates will say, "Well if I live longer but I'm miserable living longer, yes that works for regulatory agencies but doesn't work for us." So PROs clearly are very, very important. And, in fact, we just literally had a meeting in Houston, the IBCG meeting where PROs were a main point of what we discussed. So incorporating PROs in everything we do, not just this but everything we do, Dr. Necchi, myself, everybody involved in these fields realizes it is very, very important. So absolutely. Dr. Davide Soldato: I want to thank again Professor Necchi and Professor Kamat for joining us today. Dr. Andrea Necchi: Thank you. Dr. Ashish Kamat: It is our pleasure. Dr. Davide Soldato: Thanks again and we appreciate you sharing more on your JCO article titled "Endpoints for the Next Generation Bladder-Sparing Perioperative Trials for Patients with Muscle-Invasive Bladder Cancer." If you enjoy our show, please leave us a rating and review and be sure to come back for another episode. You can find all ASCO shows at asco.org/podcast. The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.

Amardeep Parmar⁠⁠⁠⁠⁠⁠⁠ from Bae HQ welcomes ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Dr. Ashish Mandavia,⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Co-founder & CEO at Sohar Health⁠⁠.Amardeep Parmar:⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://www.linkedin.com/in/amardeepsparmar⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Dr. Ashish Mandavia:https://www.linkedin.com/in/ashishmandavia/Sohar Health:https://www.soharhealth.com/

Welcome Online Family!  Join us in worshipping the King of Kings Jesus. If you have a need that we can pray for, please feel free to comment below or DM us and we would love pray with you! To support this ministry and help us continue to reach people all around the world click here: https://bit.ly/36vpxdD Subscribe to get notifications on all the latest sermons and worship covers, click on the bell icon to receive notifications every time we post! Share with your friends, colleagues, loved ones.  ------------------------------------------- Connect with us on all Commission Socials: https://linktr.ee/CommissionChurch

Ashish Ranjan is an ex-ISRO, ex- BARC Scientist. He has spent the past 5 years writing a book on his experience of getting selected and working in India's Nuclear program and how he worked his way up into India's space program despite his poor academic background. Ashish had scored 53/100 in Mathematics and 61/100 in Physics on his 12th boards. He had even failed Physics in his 11th Standard. Ashish never got admitted to top universities for his B.Tech. like IITs or NITs. Yet, he made his way into India's two of the largest research organizations as a Scientist and got selected for Masters program in IIT Bombay. He has recently published a Book, "The Boy Who Did Not Sign" which is a fictional story inspired by a true event in Ashish's life in BARC and his road to securing an AIR-4 in ISRO national level Entrance Exam. The book is about pursuing a dream career despite our limitations and disadvantages, about relationship dynamics we all face, and about doing the right thing. The Boy Who Did Not Sign is now published worldwide (Paperback + eBook).–––––––––––––––––––

In this episode of The Digital Executive, Brian Thomas interviews Ashish Aggarwal, Co-Founder of AppBroda—a no-code ad network empowering mobile app and game developers to scale revenue without writing a single line of code. Drawing on his experience at Google working with thousands of developers, Ashish explains the industry's biggest friction point: developers don't want additional SDKs or code that slow apps, risk crashes, or violate privacy rules.Ashish shares how AppBroda solves that challenge with automated, data-driven monetization tools now used by over 2,000 studios, contributing to more than $2B in annual recurring revenue. He breaks down what separates consistently successful studios—data-driven systems, adaptability, and access to capital—and how privacy shifts and platform policies have reshaped mobile ad economics.Looking ahead, Ashish predicts a new era where AI enables anyone to become an app or game creator. He explains how no-code platforms like AppBroda will power this next wave of digital entrepreneurs by simplifying monetization for non-technical builders. This conversation is a must-listen for developers, creators, and anyone following the future of mobile apps.If you liked what you heard today, please leave us a review - Apple or Spotify. See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

In this powerful episode of Fuel for the Harvest, Nathan shares an extraordinary collection of firsthand recordings from Ashish — a faithful Forge Ambassador serving in Bangladesh, one of the most densely populated and spiritually challenging Muslim nations in the world.What began as a single laborers training just six months ago has now erupted into a rapidly multiplying gospel movement. Ashish and his team have already trained over 1,000 laborers, launched 100+ cell groups, distributed hundreds of Bibles, and seen countless people — including those from Muslim backgrounds — respond to Jesus.

Are driving assistance systems making the roads safer? Ashish Agarwal, professor in the IROM Department of Management in the McCombs School of Business at The University of Texas at Austin, gets behind the wheel to find out. Ashish Agarwal is a professor of information, risk, and operations management at The University of Texas at Austin's […]

In this powerful talk, Ashish Vidyarthi dives deep into the feeling of guilt that often holds us back from making a fresh start. Whether you're thinking about changing careers, moving cities, or simply choosing a different path, this is a reminder that you don't owe anyone an explanation for your choices .Ashish shares his own vulnerable story of reinventing himself—from being a famous on-screen villain to becoming a speaker, traveler, and storyteller—and the fear he faced along the way.In this video, you'll discover:Why starting over is a sign of growth, not failure .How to release what no longer serves you, without apology or shame .That you have permission to build a life that fits who you are today .The quiet power of gently closing one door and opening another.As Ashish says, "You are allowed to begin again without apology, without shame, without guilt" . It's time to hug yourself for the journey and embrace the possibility of a new chapter .Say it with us: I AM POSSIBLE!#AshishVidyarthi #StartingOver #Motivation #LetGoOfGuilt #PersonalGrowth #Inspiration #NewBeginnings #SelfHelp #IAmPossible

Ashish Ranjan is an ex-ISRO, ex- BARC Scientist. He has spent the past 5 years writing a book on his experience of getting selected and working in India's Nuclear program and how he worked his way up into India's space program despite his poor academic background. Ashish had scored 53/100 in Mathematics and 61/100 in Physics on his 12th boards. He had even failed Physics in his 11th Standard. Ashish never got admitted to top universities for his B.Tech. like IITs or NITs. Yet, he made his way into India's two of the largest research organizations as a Scientist and got selected for Masters program in IIT Bombay. He has recently published a Book, "The Boy Who Did Not Sign" which is a fictional story inspired by a true event in Ashish's life in BARC and his road to securing an AIR-4 in ISRO national level Entrance Exam. The book is about pursuing a dream career despite our limitations and disadvantages, about relationship dynamics we all face, and about doing the right thing. The Boy Who Did Not Sign is now published worldwide (Paperback + eBook).–––––––––––––––––––

Do you ever wake up feeling overwhelmed, misunderstood, or that life is just too heavy to carry?In this heartfelt and moving podcast, Ashish Vidyarthi shares a powerful message for everyone navigating a difficult chapter.Life isn't always about winning; sometimes, it's about acknowledging that you're not okay and finding the strength to take just one more step.Ashish talks about his own struggles as a self-employed actor facing rejection and uncertainty, and how these moments pushed him to discover new paths as a vlogger, speaker, and innovator.In this episode, you will discover:Why it's crucial to be "okay with not being okay".How to choose your response, even when you can't control what's happening around you.The power of "tiny wins" to build momentum and shift your mindset.How to reframe the question from "Why is this happening to me?" to "What is life pushing me towards?".The strength in reaching out for help and sharing your truth.This isn't just a lecture; it's a gentle reminder that you are not stuck, you are not alone, and your story is still being written by you. Remember, I Am Possible.If this message resonates with you, please Like, Share, and Subscribe for more conversations that uplift and inspire.What's one "tiny win" you can gift yourself today?#AshishVidyarthi #Motivation #Inspiration #WhenLifeFeelsHeavy #MentalWellness #SelfHelp #PositiveThinking #DealingWithFailure #OvercomingObstacles #IAmPossible

Have you ever been made to feel small, unworthy, or invisible? In this powerful episode, Ashish Vidyarthi shares his personal experiences and heartfelt advice on how to deal with being looked down upon.In a world where it's easy to feel dismissed, Ashish explains that no one can make you feel small unless you give them that right. This episode is a guide to rewriting the negative stories you tell yourself and reclaiming your power.In this video, you will learn:Why someone looking down on you is more about their own insecurities than it is about you.The power of changing your inner narrative from "I'm not good enough" to "I am who I choose to become".Practical steps to rise above negativity without anger or revenge.Why your growth is the most powerful response to those who doubt you.The importance of becoming your own biggest cheerleader and celebrating your journey.Join Ashish as he guides you to stop seeking validation from others and start building unshakable self-worth. It's time to walk tall, keep your spirit high, and remember: I Am Possible.#AshishVidyarthi #Motivation #SelfWorth #Inspiration #PersonalGrowth

What if working less could help us live more — with greater energy, purpose, and joy?In this eye-opening conversation, Ashish Kothari sits down with Karen Lowe, South Africa's lead advocate for the 4-Day Workweek movement and founder of 4 Day Week South Africa, to explore how shorter work weeks are transforming productivity, culture, and well-being across the globe.Karen shares how a passion project in Cape Town became the world's fourth major pilot of the 4-Day Workweek — and the results are nothing short of revolutionary: higher revenue, lower burnout, better sleep, deeper engagement, and teams that flourish together.This episode challenges the modern obsession with “more” and makes a powerful case for the 4-day week as both a science-backed productivity strategy and a human sustainability movement.

Join us in worshipping the King of Kings Jesus. If you have a need that we can pray for, please feel free to comment below or DM us and we would love pray with you! To support this ministry and help us continue to reach people all around the world click here: https://bit.ly/36vpxdD Subscribe to get notifications on all the latest sermons and worship covers, click on the bell icon to receive notifications every time we post! Share with your friends, colleagues, loved ones.  ------------------------------------------- Connect with us on all Commission Socials: https://linktr.ee/CommissionChurch

In a world that constantly demands more from us—more hustle, more achievement, more success—it's easy to feel guilty for slowing down. But what if pausing isn't a sign of weakness, but a source of strength?In this episode of "I Am Possible AV," join Ashish as he shares his personal journey of learning to embrace rest. From pushing through physical pain as an actor to navigating the mental toll of constant pressure, he reveals the powerful lessons discovered in the quiet moments of pause.If you're feeling tired, burnt out, or overwhelmed by the need to always be "on," this message is for you. Discover why rest is not laziness, but essential preparation for your next chapter.Key messages in this talk:There is grace in resting and strength in slowing down.Rest is a form of rejuvenation and a time for discovery.Pushing yourself too hard can lead to physical and mental burnout.Healing begins when you give yourself permission to take care of yourself.#Motivation #SelfCare #Burnout #MentalHealth #Rest #Inspiration #Podcast

Grow your management tools for opioid withdrawal in the hospital. Investigate how to decide between methadone and buprenorphine, additional medications to manage symptoms and how and when to use short-acting opioids for management of withdrawal. We're joined by Ashish Thakrar, MD at the University of Pennsylvania.  Claim CME for this episode at curbsiders.vcuhealth.org! By listening to this episode and completing CME, this can be used to count towards the new DEA 8-hr requirement on substance use disorders education. Episodes | Subscribe | Spotify | iTunes | CurbsidersAddictionMed@gmail.com | CME! Show Segments Intro, disclaimer, guest bio Guest one-liner Case from Kashlak; Definitions Symptoms of opioid withdrawal Medications for the management of opioid withdrawal Buprenorphine precipitated withdrawal Starting Buprenorphine: Experiences and Strategies  Titrating Methadone: Dosage and Adjuncts Adjunctive short-acting opioids Emerging Trends in Drug Supply: Xylazine and Medetomidine Outro Credits Producer, Show Notes: Zina Huxley-Reicher Infographics: Zina Huxley-Reicher MD and Zoya Surani Hosts: Carolyn Chan, MD MHS, Zina Huxley-Reicher MD, Shawn Cohen, MD Reviewer: Payel Jhoom Roy, MD, MSc Showrunner: Carolyn Chan, MD, MHS Technical Production: PodPaste Guest: Ashish Thakrar, MD MHSP

What if the most painful moments in life could become the greatest catalysts for growth?In this deeply moving episode of The Flourishing Edge, Ashish Kothari sits down with Ian Ziskin, President of EXec EXcel Group LLC, author, and leadership thought leader, to explore the powerful connection between loss, learning, and leadership.Ian shares the personal story that shaped his life from age 13 — losing his father to multiple sclerosis — and how that early experience of grief forged his lifelong commitment to intentional living, compassion, and resilience. Together, Ashish and Ian unpack what it truly means to flourish through adversity, why intentionality (not time) heals wounds, and how leaders can create workplaces where people feel trusted, valued, and alive.This episode is a masterclass in transforming suffering into strength — and leading with both heart and purpose.

Welcome Online Family!  Join us in worshipping the King of Kings Jesus. If you have a need that we can pray for, please feel free to comment below or DM us and we would love pray with you! To support this ministry and help us continue to reach people all around the world click here: https://bit.ly/36vpxdD Subscribe to get notifications on all the latest sermons and worship covers, click on the bell icon to receive notifications every time we post! Share with your friends, colleagues, loved ones.  ------------------------------------------- Connect with us on all Commission Socials: https://linktr.ee/CommissionChurch

Every five years, resuscitation guidelines get a refresh. This year, a few have changed, many have stayed the same, and some are creating major controversy.In this episode, Dr. Ashish Panchal, Chair of the AHA Emergency Cardiovascular Care Committee, helps us unpack what's new, what might surprise you, and the science behind each decision. You'll learn why there's serious debate around epinephrine dosing, what changes matter most for the bedside, and how these updates will change the way you and your team respond to the next code!Topics discussed in this episode:The history and development of the AHA Resuscitation GuidelinesKey improvements: algorithms, clear language, and unified careBig, fundamental changes in the guidelinesHow choking management guidelines have changedThe recommended approach for synchronized cardioversionNew guidelines for post-resuscitation careWhy there's controversy around mechanical CPR and DSDIV vs. IO access: best practice and key takeawaysThe controversy around epinephrine dosingWhat these changes mean for nurses and code teamsListen to E140 with Dr. Ashish Panchal:https://healthpodcastnetwork.com/episodes/rapid-response-rn/140-resuscitation-then-and-now-how-evidence-shapes-every-beat-with-guest-dr-ashish-panchal-md-phd/Mentioned in this episode:AND If you are planning to sit for your CCRN and would like to take the Critical Care Academy CCRN prep course you can visit https://www.ccrnacademy.com and use coupon code RAPID10 to get 10% off the cost of the course!CONNECT

In this inspiring episode of TBCY, host Sandeep Tyagi sits down with Ashish Kumar Chauhan, the Managing Director and CEO of the National Stock Exchange of India (NSE), known as the father of modern financial derivatives in India. Ashish shares his incredible journey from a small village in Gujarat to building India's most advanced stock exchange and pioneering technological revolutions in the financial ecosystem. Discover behind-the-scenes stories from the founding days of NSE, challenges faced, and his philosophy of "Sthit Pragya"—maintaining equilibrium in the face of ambition and adversity.We dive deep into the evolution of India's capital markets, retail investor participation, the transformative power of technology like AI in finance, and valuable career advice for young professionals. Ashish also opens up about his personal life, values, and passions beyond work, including his love for cricket and social causes.Whether you're interested in finance, technology, or personal growth, this episode is packed with wisdom, anecdotes, and reflections from one of India's most influential financial leaders.

In this compelling episode of Career Club Live, Bob Goodwin sits down with global pharmaceutical executive Ashish Pal to explore the essence of impactful leadership. Drawing from a rich international career across specialty and large-scale pharma organizations, Ashish introduces his personal leadership model—the Leadership Triangle, built on People, Strategy, and Operations. Ashish reflects on the early experiences that shaped his leadership style, including a bold product launch that redefined a category and expanded a stagnant market. His story is a masterclass in thoughtful risk-taking, team empowerment, and cultivating a culture where it's safe to fail—and essential to dream big. Together, Bob and Ashish dive into what makes great teams tick, how to navigate ambiguity with confidence, and why humility, learning agility, and fun are just as important as technical proficiency. Ashish's insights are deeply human, refreshingly practical, and globally resonant. Key Themes: Building teams like a tapestry—diverse, intentional, and aligned Moving from fear-based decision-making to bold, confident execution The critical difference between strategy and operationalization What leaders can do to foster psychological safety, curiosity, and grit Whether you're a rising professional or a seasoned executive, this episode will challenge you to rethink how you lead—and who you bring with you.  Listen now on Apple Podcasts or Spotify

Welcome Online Family!  Join us in worshipping the King of Kings Jesus. If you have a need that we can pray for, please feel free to comment below or DM us and we would love pray with you! To support this ministry and help us continue to reach people all around the world click here: https://bit.ly/36vpxdD Subscribe to get notifications on all the latest sermons and worship covers, click on the bell icon to receive notifications every time we post! Share with your friends, colleagues, loved ones.  ------------------------------------------- Connect with us on all Commission Socials: https://linktr.ee/CommissionChurch

Namaskar, Dear friend,In this powerful episode, Ashish Vidyarthi explores the tension between the mirage we chase and the reality we live. From EMI pressure, FOMO, and Insta validation to lessons from Mahabharat's Maya Sabha, this talk is a candid reminder to live within our means and choose peace over pretense.What you'll hear:The cost of appearing successful vs living truthfully“If your lifestyle is richer than your bank balance, your peace will be poorer than your Instagram bio.”Duryodhan and the illusion of comparison (Maya Sabha)Personal money lessons: credit card debt, auto-pay discipline, and second-hand carsWhy simplicity is clarity—not povertyHappiness is in enough, not excessLandmark Forum insight: “The money you have is the money you have.”Core message:Lifestyle should follow reality, not insecurityEnjoy luxuries when they're earned, not borrowedPublic happiness shouldn't be private painLive your truth—because respect follows authenticity.If this resonated, share it with someone feeling the pressure to “keep up.”Cheers to love, and to your amazing reality.#AshishVidyarthi #IAmPossible #PersonalFinance #Minimalism #Mindset #FOMO #DebtFree #Authenticity #Mahabharat #LifeLessons

Technology promised us progress, and it delivered. But it also left us disconnected, distracted, and disheartened at the same time. With AI advancing faster than human adaptation or regulation, will it erode our humanity, or can it become the very tool that helps us flourish?In this episode of the Happiness Squad Podcast, Ashish Kothari sits down with Tamara Lechner to explore how AI can bridge the gap between what we know and what we practice in the pursuit of human flourishing.Tamara Lechner is a happiness expert, author, and global speaker. As Chair of the AI & Human Flourishing Working Group at Harvard, she helps leaders and organizations apply the science of flourishing to create meaningful, human-centered futures.In the conversation, Ashish and Tamara unpack how AI can either harm or uplift us, and what it will take for leaders, organizations, and individuals to put humans at the heart of this powerful technology.Things you will learn in this episode:• Why AI is both friend and foe depending on how we use it.• The three ethical AI pillars: productivity, protection from harm, and fairness.• The overlooked dimensions of flourishing AI must support• Why organizations—not just individuals—must own responsibility for burnout and culture.• How to shift from audience to activist in shaping the future of technologyJoin us in building a future where technology enhances humanity rather than diminishes it. Tune in now to hear how we can harness AI to truly help humans flourish.✅Resources:• How to make flourishing your competitive edge | Ashish Kothari | TEDxGreenhouse Road: https://www.youtube.com/watch?v=eRV-2C-fkNg • AI for Human Flourishing: https://www.aiforhumanflourishing.com/• The Human Flourishing Program: https://hfh.fas.harvard.edu/ai-human-flourishing • Reframing employee health: Moving beyond burnout to holistic health by McKinsey Health Institute: https://www.mckinsey.com/mhi/our-insights/reframing-employee-health-moving-beyond-burnout-to-holistic-health• Conscious Capitalism Movement: https://www.consciouscapitalism.org/ • IEEE 7010: A New Standard for Assessing the Well-being Implications of Artificial Intelligence: https://arxiv.org/pdf/2005.06620 ✅Books:• The Happiness Reset: What to do When Nothing Makes You Happy by Tamara Lechner: https://a.co/d/gZY7eXu • Hardwired for Happiness: 9 Proven Practices to Overcome Stress and Live Your Best Life by Ashish Kothari: https://a.co/d/9LWxYmV

What if the TV in your living room could help your aging parent stay engaged, connected, and cared for—without learning a single new device?In this episode of The Aging Well Podcast, Dr. Jeff Armstrong is joined by Ashish Aggarwal, CEO and co-founder of JubileeTV, a revolutionary smart TV-based platform built specifically to support older adults and their caregivers. With both of his parents living with dementia, Ashish brings not just technical expertise, but deep personal empathy to the challenges of aging in place.Together, they explore how JubileeTV is using accessible design, real-time communication, and AI-powered tools to reduce isolation, ease caregiver stress, and reimagine what aging with dignity can look like in the 21st century.Whether you're a caregiver, a professional in aging services, or simply thinking about the future of aging, this conversation offers real hope—and practical tools—for living and caring better.Learn more about JubileeTV at https://getjubileetv.com/Please, support The Aging Well Podcast by hitting the ‘like' button, subscribing/following the podcast, sharing with a friend, and….BUY the products you need to… age well from our trusted affiliates and support the mission of The Aging Well Podcast*.The Aging Well Podcast merchandise | Show how you are aging well | Use the promo code AGING WELL for free shipping on orders over $75 | https://theagingwellpodcast-shop.fourthwall.com/promo/AGINGWELLRebalance Health | products created by hormone health experts to lower cortisol, improve sleep, and minimize the impact of stress on the body and mind | https://get.aspr.app/SH1AkZ or https://rebalancehealth.com with the promo code: AGING WELLAuro Wellness | Glutaryl—Antioxidant spray that delivers high doses of glutathione (“Master Antioxidant”) | 10% off Code: AGINGWELL at https://aurowellness.com/agingwellpodcast Berkeley Life | Optimize nitric oxide levels | Purchase your starter kit at a 15% discount | Use the promo code: AGINGWELL15 | https://berkeleylife.pxf.io/c/6475525/3226696/31118Oxford Healthspan | Primeadine®, a plant-derived spermidine supplement | 10% off code: AGINGWELL | https://oxford-healthspan.myshopify.com/AgingWellJigsaw Health | Trusted supplements. “It's fun to feel good.” | Click the following link for 10% off: https://www.jigsawhealth.com/?rfsn=8710089.1dddcf3&utm_source=refersion&utm_medium=affiliate&utm_campaign=8710089.1dddcf3Prolon | The Fasting Mimicking Diet (FMD) is a revolutionary five-day nutrition program scientifically formulated to mimic the effects of a prolonged water fast while still allowing nourishment - supporting the benefits of fasting without the challenges and risks that come from water-only fasts. | For the best available discount always use this link: https://prolonlife.com/theagingwellpodcastL-Nutra Health | The medical division of L-Nutra, focused on helping people manage and potentially reverse chronic health conditions, like type 2 diabetes, prediabetes, insulin resistance, and obesity, using personalized, lifestyle-based programs grounded in evidence, not prescriptions. | Use this link: https://l-nutrahealth.com/theagingwellpodcastThrive25—Your personal longevity advisor | https://www.thrive25.com/early-access?via=william-jeffreyFusionary Formulas | Combining Ayurvedic wisdom with Western science for optimal health support. | 15% off Code: AGINGWELL | https://fusionaryformulas.com?sca_ref=9678325.IHg5xYhdOzzke8ZrDr Lewis Nutrition | Fight neurodegeneration and cognitive decline with Daily Brain Care by Dr Lewis Nutrition—a proven daily formula designed to protect and restore brain function. | 10% off code: AGINGWELL or use the link: https://drlewisnutrition.com/AGINGWELL*We receive commission on these purchases. Thank you.

How do you know whether an iOS app you have built has potential to be big? Getting an email from Steve Jobs is probably a strong indicator.Ashish Toshniwal, founder of 10Kr and YML (Y Media Labs), started by trying a bit of everything: classifieds, Groupons, and Facebook apps. That email made him quit his job, but as Ashish says, it took him and YML 14 years to become an overnight success. YML helped businesses go mobile-first long before it became a buzzword, with over 45 Fortune 500 clients including Apple, PayPal, Meta, and Disney. Along the way, Ashish shares the real decisions every founder faces, such as when to take VC money, when to sell, and how to think about repeat business. He also reflects on turning down opportunities like Credit Karma equity (now worth $7billion), showing the tough choices early-stage founders make just to survive and keep their business running.This is a story about timing, focus, and conviction, and what happens when you build something real: from Calcutta to Silicon Valley, one decision at a time.0:00 – Trailer03:24 – How the Co-founders met05:28 – The first 3 ideas: Classifieds, Groupons & Facebook apps06:30 – An email from Steve Jobs made Ashish quit his Job07:59 – Building apps when App Store launched (Apple as a client too)09:20 – YML was famous but not profitable10:07 – Becoming the “app guys” of Silicon Valley11:56 – The pivot: Stick with products or move to services?13:43 – 6 acquisition offers on the table: Sell or not?16:57 – The first exit: 60% acquired at $60M18:38 – “We'd never seen that kind of money”19:26 – IOS engineering was like AI engineering20:13 – “If we don't have repeat business, we don't have business”22:09 – Silicon valley is not a zipcode, it's a mindset23:54 – Clients came for design, stayed for engineering26:11 – Does motivation change when equity shrinks?29:01 – Firing and re-hiring yourself as founder CEO30:50 – Why the final decision to sell YML was made32:55 – The golden window of mobile34:26 – Could YML have been a billion-dollar company?37:34 – Turning down Credit Karma equity: now worth $7B38:39 – Why CEOs are like travel agents41:50 – Why Ashish invested in Neon44:22 – What wealth truly enables47:36 – Investing early in Tesla, Nvidia, and Meta49:07 – Why founder-led companies outperform in public markets50:54 – It's easy to build products, harder to build real businesses52:44 – If your product isn't 10x better than ChatGPT, you have no chance53:04 – The future of jobs: 5 roles merging into 2 with agents on top57:25 – ChatGPT will not go after human-in-the-loop59:35 – The first real challenge to Google's dominance1:01:59 – Building AI agents that do real work is incredibly hard-------------India's talent has built the world's tech—now it's time to lead it.This mission goes beyond startups. It's about shifting the center of gravity in global tech to include the brilliance rising from India.What is Neon Fund?We invest in seed and early-stage founders from India and the diaspora building world-class Enterprise AI companies. We bring capital, conviction, and a community that's done it before.Subscribe for real founder stories, investor perspectives, economist breakdowns, and a behind-the-scenes look at how we're doing it all at Neon.-------------Check us out on:Website: https://neon.fund/Instagram: https://www.instagram.com/theneonshoww/LinkedIn: https://www.linkedin.com/company/beneon/Twitter: https://x.com/TheNeonShowwConnect with Siddhartha on:LinkedIn: https://www.linkedin.com/in/siddharthaahluwalia/Twitter: https://x.com/siddharthaa7-------------This video is for informSend us a text

Send us a textThe digital front door to healthcare is jammed, and it's costing patients, providers, and payers alike.In this episode of CareTalk Executive Features, host David Williams talks with Dr. Ashish Mandavia, CEO and cofounder of Sohar Health, about how AI and automation can transform eligibility and benefits verification from a frustrating bottleneck into a seamless, real-time process.

Welcome Online Family!  Join us in worshipping the King of Kings Jesus. If you have a need that we can pray for, please feel free to comment below or DM us and we would love pray with you! To support this ministry and help us continue to reach people all around the world click here: https://bit.ly/36vpxdD Subscribe to get notifications on all the latest sermons and worship covers, click on the bell icon to receive notifications every time we post! Share with your friends, colleagues, loved ones.  ------------------------------------------- Connect with us on all Commission Socials: https://linktr.ee/CommissionChurch

Discover how Ashish Gupta, CEO of ScaleUpExec, helps businesses scale, navigate crises, and transform cultures with fractional leadership and practical spirituality. Learn the power of strategy, execution, and inner stability in high-stakes decision-making.00:33- About Ashish GuptaAshish is the CEO of ScaleUpExec.

Namaskar! Welcome to "I Am Possible AV" – an inspiring journey led by Ashish Vidyarthi where we break free from labels, professions, and self-limiting beliefs. In this episode, Ashish shares powerful stories and insights on evolving beyond your comfort zone, starting over, and daring to pursue a life of possibilities at any age. Are you feeling stuck or craving something different? Have you let success or failure box you in? Do you want to embrace new passions, careers, or adventures—no matter your age or past?You'll learn:How to break free from typecasting and "labels"That it's never too late to begin again and choose a new pathWhy age, past success, or failure should never hold you backHow taking new steps leads to personal liberation and growthReal-life stories of reinvention, including Ashish's journey from actor to motivational speaker, vlogger, and beyondThis episode is for everyone—whether you're just starting, seeking change, or ready to add new chapters to your life.Say with us: "I am [Your Name] and I am open to becoming whoever I am inspired to be next!" Subscribe for more motivational stories and actionable inspiration! Like, comment, and share your own story of reinvention!#IAmPossibleAV #ReinventYourself #Motivation #Inspiration #AshishVidyarthi #Podcast #NewBeginnings #NeverTooLate #BreakTheBox #PersonalGrowth

In this episode, Madhavi Ravanan, Engineering Leader at Nokia, interviews Ashish Agrawal, Managing Director at Nagarro. Ashish reflects on Hermann Hesse's Siddhartha — exploring themes of wisdom, balance, and letting go. He shares how the book has influenced his personal and professional life, discussing the power of experience over knowledge, the meaning of parenthood, and the idea that true peace comes when we stop searching and start living. 00:00 Introduction and Guest Welcome 01:00 Driving Non-Linear Growth at Nagarro 01:45 The Habit of Reading 03:30 Why Siddhartha? 05:45 The Message of Letting Go 08:15 Learning Through Experience, Not Knowledge 11:00 Parenting and the Circle of Life 13:45 Balance Over Extremes 16:30 Soft Is Stronger Than Hard 20:00 Truth Has Two Sides 23:00 The Inward Journey 25:30 Let Life Happen to You 28:30 Closing Thoughts and Reflections

This is the story of Kriti's Labor and Birth and how they made the decisions moving through each phase. The highlight of the story is 'Self direction' . It is not important where you really birth, what is important at the core of it all is how 'self directed' a family is in their birth choices. Kriti and Ashish are a grounded couple who take time to decide what is good for them, they listen in and are great examples of strength, inner strength. There is vulnerability and charm in their story. Discussion points:Passing Due Date and the start of spontaneous labor.Partner's support during Labor and Birth.How Labor Pain feels in the body.Sleep during LaborDecision to transfer to the hospital.The experience at the hospitalExperience of Breastfeeding and how our bodies as women can hold so much.Experience of Breastfeeding as healing and liberatingKriti is the founder of the permaculture farm ‘Slowness Himalayas'. Natural dyer and ethnobotanist. Find her on insta: @digitalbatuttaSupport the showSign up for Childbirth Preparation Programs! visit https://birthagni.com/services#childbirth-preparation-programs https://birthagni.com/copy-of-services#breastfeeding-preparation-program This episode is supported and made possible by podcast recording and hosting tool Zencastr, it is impeccably made! Use my link : https://zen.ai/vxmuJUgYKKGTF3JuTuFQ0g to sign up and record flawless remote podcast , USE my code : BIRTHAGNI Support the show:https://birthagni.com/birthagnipodcast#donate If you like what you hear, leave us a rating on Spotify app and answer the question at each episode! a review on Apple podcasts. Share on Whatsapp/Insta/FB Share on Instagram and tag us @divyakapoorvox ...

Small and medium businesses make up nearly half of all employment and GDP, yet they often struggle to compete against the scale, brand power, and resources of large corporations. Too often, the advice given to them is to “play bigger”—but that's a losing battle. What if the real advantage lies in embracing their underdog status?In this episode of the Happiness Squad Podcast, Ashish Kothari sits down with Sri Kaza, Advisory Board at Markaaz and author of the upcoming book UNCONVENTION: A Small Business Strategy Guide, to explore how SMBs can thrive by leaning into what makes them different: positioning, proximity, and purpose. They discuss why small doesn't mean weak, and how founders can unlock resilience, loyalty, and growth by playing their own game.Sri Kaza is an entrepreneur, investor, and former McKinsey consultant with a career spanning engineering, consulting, finance, and startups. He has helped scale visionary companies like Viking Cruises, co-founded ForwardLine to provide innovative financing for small businesses, and worked closely with entrepreneurs across industries to unlock growth. Ashish and Sri unpack inspiring stories, actionable insights, and practical strategies that will change the way you think about leading and growing a small to medium business. Tune in to discover how to turn your size into your greatest strength.Things you will learn in this episode:• The three Underdog Principles—Positioning, Proximity, and Purpose—and how to apply them• Why focusing on your core customers builds resilience during crises• How closeness to employees and community becomes a competitive edge• How AI can serve as a growth engine for SMBs rather than just a cost-cutting tool• Practical ways to stay grounded as a founder and align every decision with purposeIf you want to discover how small and medium businesses can outcompete giants and make flourishing their competitive edge, this conversation is one you won't want to miss.✅Resources:• How Great Companies Deliver Both Purpose and Profit by Alex Edmans: https://corpgov.law.harvard.edu/2020/10/01/how-great-companies-deliver-both-purpose-and-profit/ ✅Books:• Unconvention: A Small Business Strategy Guide by Sri Kaza: https://a.co/d/aYYfD8w • The Experimentation Machine by Jeff Bussgang: https://experimentationmachine.com/• Hardwired for happiness by Ashish Kothari: https://happinesssquad.com/hardwired-for-happiness/

Welcome to a heartfelt episode of the "I Am Possible" podcast with Ashish Vidyarthi. In this empowering conversation, Ashish dives deep into how to handle trolls, respond to feedback, and truly live your own story despite the chatter of the world. Discover:The reality of dealing with judgments & online commentaryDifferentiating between constructive feedback and trollingInspiring real-life examples of powering through criticismHow to stay true to your passion, dreams, and whyActionable tips for filtering noise and embracing positive voicesIf you've ever felt held back by what others are saying—especially on social media or in your community—this episode is for you! What is your "chai"? Where do you want to enjoy it? This is YOUR journey. Subscribe for more motivational conversations and let us know in the comments: How do YOU handle feedback and negativity?#AshishVidyarthi #Trolls #Feedback #LiveYourStory #Podcast #Motivation #MentalWellness #LifeLessons

What truly drives people to thrive at work isn't perks or programs, but the culture leaders create every single day. But when the day-to-day culture at work is marked by fear, unclear roles, and pressure from the top, people disengage no matter how many benefits you offer. Leaders often miss this because they're chasing quarterly targets or process checklists, leaving human potential untapped. Grace Zuncic's journey from small-town roots to Chobani, Cotopaxi, and now Manna Tree Partners shows a different path.In this episode of the Happiness Squad Podcast, Ashish Kothari and Grace Zuncic explore how flourishing comes when work itself is designed around courage and kindness.Grace Zuncic is a seasoned executive and board member with deep experience in scaling purpose-driven companies. She has held leadership roles at Chobani, Cotopaxi, and now serves as Partner at Manna Tree, a private equity firm focused on improving human health through investment in food and wellness businesses.In the conversation, Ashish and Grace highlight why the answer isn't to bolt wellbeing programs onto broken systems but to build workplaces where flourishing is the operating model—unlocking both human potential and business performance.Things you will also learn in this episode:• Why fear is the biggest barrier to flourishing at work• How Chobani became a model of human-centered leadership during COVID• The role of courage and kindness in effective leadership• Why private equity has more influence on culture than it realizes• How board service shapes perspective on building enduring, purpose-driven companiesDon't miss this episode—an urgent call for leaders to lead with courage, act with kindness, and create workplaces where people can truly flourish.✅Resources:• How to Make Flourishing Your Competitive Edge: https://www.youtube.com/watch?v=eRV-2C-fkNg • What Does a Compassionate Workplace Look Like? With Jane Dutton and Monica Worline: https://greatergood.berkeley.edu/article/item/what_does_compassionate_workplace_look_like • The Cotopaxi Foundation: https://www.cotopaxi.com/pages/our-impact?srsltid=AfmBOoqOcdspf6JmJREdKix62bge5cFMOpEioKkGK1xVMs76EY1mrIUg • Women on Boards: https://www.womenonboards.net/• Tugboat Institute: https://www.tugboatinstitute.com/ ✅Books:• Shift by Ethan Cross: https://a.co/d/8ioBnAM • Man's Search for Meaning by Viktor Frankl: https://a.co/d/aj9Uubw • Everybody Matters by Bob Chapman and Raj Sisodia: https://a.co/d/4AWqNws • Ray Dalio's Principles: https://a.co/d/5wfMHzQ • Another Way by Dave Wharton: https://a.co/d/gPnSTGC • You Are Here by Thich Nhat Hanh:

Kriti and Ashish left behind a city life to build a farm and live in a remote village - all because it meant a slower life of connection. "We would not have had a baby had we been in the city", Kriti says and then goes on to share how living with nature, they started craving to have a third energy in her own words in the world around them.In this episode, Kriti also shares how the collective women echoed a sense of strength in birth but when she went the regular route of going to a doctor, they were always reminded to be cautious , not joyous. This contrast and an episode of misconduct from the doctor shifted their approach to a more natural birth .Tune in to hear us discuss:Kriti's journey of PregnancyThe Women's experience and wisdomm of Birth around her.The circumstances with the doctor that led to a shift in their approach.The decision to birth at homeThe choice of a local dai to support themKriti is the founder of the permaculture farm ‘Slowness Himalayas'. Natural dyer and ethnobotanist. Find her on insta: @digitalbatuttaSupport the showSign up for Childbirth Preparation Programs! visit https://birthagni.com/services#childbirth-preparation-programs https://birthagni.com/copy-of-services#breastfeeding-preparation-program This episode is supported and made possible by podcast recording and hosting tool Zencastr, it is impeccably made! Use my link : https://zen.ai/vxmuJUgYKKGTF3JuTuFQ0g to sign up and record flawless remote podcast , USE my code : BIRTHAGNI Support the show:https://birthagni.com/birthagnipodcast#donate If you like what you hear, leave us a rating on Spotify app and answer the question at each episode! a review on Apple podcasts. Share on Whatsapp/Insta/FB Share on Instagram and tag us @divyakapoorvox ...

Welcome Online Family!  Join us in worshipping the King of Kings Jesus. If you have a need that we can pray for, please feel free to comment below or DM us and we would love pray with you! To support this ministry and help us continue to reach people all around the world click here: https://bit.ly/36vpxdD Subscribe to get notifications on all the latest sermons and worship covers, click on the bell icon to receive notifications every time we post! Share with your friends, colleagues, loved ones.  ------------------------------------------- Connect with us on all Commission Socials: https://linktr.ee/CommissionChurch

If you enjoy this episode, we're sure you will enjoy more content like this on The Occult Rejects.  In fact, we have curated playlists on occult topics like grimoires, esoteric concepts and phenomena, occult history, analyzing true crime and cults with an occult lens, Para politics, and occultism in music. Whether you enjoy consuming your content visually or via audio, we've got you covered - and it will always be provided free of charge.  So, if you enjoy what we do and want to support our work of providing accessible, free content on various platforms, please consider making a donation to the links provided below.  Thank you and enjoy the episode!Links For The Occult Rejects and The Spiritual Gangsters https://linktr.ee/theoccultrejectsOccult Research Institutehttps://www.occultresearchinstitute.org/Cash Apphttps://cash.app/$theoccultrejectsVenmo@TheOccultRejectsBuy Me A Coffeebuymeacoffee.com/TheOccultRejectsPatreonhttps://www.patreon.com/TheOccultRejectsVanessa's Tie Dye stuffhttps://www.etsy.com/shop/TruthAndDyesInstagram @truthanddyestruthanddyes@gmail.comRebirthhttps://rebirthoftheword.com/Dark Floridahttps://podcasts.apple.com/gb/podcast/dark-florida/id1780031080https://www.youtube.com/@UCpYXWSmtFWJPsk_0zvla91Q Broadcasting seedshttps://linktr.ee/broadcastingseedspodcast?fbclid=PAZXh0bgNhZW0CMTEAAafB-vxGCwEk1AchGQ6jndxIyyw_VhPT7yOZfhu1rIT7i8ZbV115DZH8EHIx-w_aem_WLRq0IM0JPmfGyDY2YFwawRicardohttps://linktr.ee/inst_for_natural_philosophyhttps://x.com/RicardoCalvrio1https://independent.academia.edu/InstituteForNaturalPhilosophyEvents The Occult Rejects will be atOctober 4 - Bigfoot Comicon, The Factory 1024 at Georgia Rd, Franklin, NC 28734October 18th - Charlies Beyond Belief at Tropical Lodge 56 F & AM Fort Myers, FLhttps://www.charliesbeyond.com/October 25-26, ARKANSAS PARANORMAL EXPO at 503 East Ninth, Little Rock, ARhttps://www.arkansasparanormalexpo.com/November 1 Greenville SC TBANovember 22 - UFO Comicon, N Broad St,US Army National Guard Armory, Mooresville, NC 28115 Mooresville, NC December 5-6 - ArtComicon, Mt. Airy, GA (Authors, Artists, Filmmakers) TBA

Ashish Mathur from Roundtable, Ahn Fire Digital, and the Dallas Hoops Journal is here talking about "Da' Bulls". He and Gerald go over the options for the team in their quest to burst out of the land of mediocrity, and wonder if they could be a surprise team in the Eastern Conference. They talk about which pieces on the Bulls roster should stay and be a part of the team's future, and which ones should be moved on to other teams. Plus, as someone who writes on the Lakers, you know he has thoughts on the season outlook for Los Angeles as well. It's time to head to the Windy City as we're talking the season outlook for the Chicago Bulls on the latest Lakers Fast Break podcast! (recorded before Josh Giddey's new contract at 4 years/100 million dollars)Follow Ashish today on Twitter @amathur25 and  @amathur2556  Follow Dripshow @dripshowshop on Instagram and buy his custom products today!Check out Dodgers baseball on Playback at https://www.playback.tv/thejoesorooxperimentJoe's new game Coreupt is OUT NOW! Wish List it here: https://store.steampowered.com/app/23... Lakers Fast Break now has YouTube memberships! Join today at / @lakersfastbreak and for just $2.99 a month, you get access to LFB badges and emojis, channel page recognition, and more! Check out Stone Hansen on Twitter @report_court, Alfred Ezman @alfredezman, and John Costa's channels: Clutch Talk- / @clutchtalkpod and Lakers Corner- / @lakerscorner and Legend350 on his new channel / @sportslegend2018 Special Deals today from our friends at #temu today at https://temu.to/m/u1samwbo8cc use code: aca785401 and you might save some $$$ at TEMU! Take a look at the line of Kinhank Mini PC's and retro game machines today at https://www.kinhank-retrogame.com?rs_ref=e8NA2Rm2 for some gaming and computing fun from Kinhank! Don't forget to watch the Lakers games with us LIVE at playback.tv/lakersfastbreak and our newest Lakers Fast Break merchandise site is now up at ⁠http://tinyurl.com/yerbtezk check it out! Please Like, Share, and Subscribe to our channel and our social media @lakersfastbreak on Twitter, Instagram, Facebook, Twitch, on BLUESKY at @lakersfastbreak.bsky.social, e-mail us lakersfastbreak@yahoo.com or catch our audio of the Lakers Fast Break today at ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://anchor.fm/lakers-fast-break⁠, Spotify, Apple Podcasts, or your favorite podcast outlet! The views and opinions expressed on the Lakers Fast Break are those of the panelists or guests themselves and do not necessarily reflect the official policy or position of the Lakers Fast Break or its owners. Any content or thoughts provided by our panelists or guests are of their opinion and are not intended to malign any religion, ethnic group, club, organization, company, individual, anyone, or anything. Presented by our friends at ⁠⁠⁠⁠⁠⁠⁠⁠⁠lakerholics.com⁠⁠⁠⁠⁠⁠⁠⁠⁠, ⁠⁠⁠⁠⁠⁠⁠⁠⁠lakersball.com⁠⁠⁠⁠⁠⁠⁠⁠⁠, ⁠⁠⁠⁠⁠⁠⁠⁠⁠Pop Culture Cosmos⁠⁠⁠⁠⁠⁠⁠⁠⁠, ⁠⁠⁠⁠⁠⁠⁠⁠⁠Inside Sports Fantasy Football⁠⁠⁠⁠⁠⁠⁠⁠⁠, ⁠⁠⁠⁠⁠⁠⁠⁠⁠DripShow Shop⁠⁠⁠⁠⁠⁠⁠⁠⁠, ⁠⁠⁠⁠⁠⁠⁠⁠⁠SynBlades.com⁠⁠⁠⁠⁠⁠⁠⁠⁠, ⁠⁠⁠⁠⁠⁠⁠⁠⁠YouTube's John Mikaelian⁠⁠⁠⁠⁠⁠⁠⁠⁠, the novel Congratulations, You Suck (available at Amazon and Barnes and Noble), ⁠⁠⁠⁠⁠⁠⁠⁠⁠The Happy Hoarder⁠⁠⁠⁠⁠⁠⁠⁠⁠, EmpireJeffTV, and ⁠⁠⁠⁠⁠⁠⁠⁠⁠Retro City Games!

Health care executive Ashish Mandavia discusses his article "Why U.S. health care pricing is so confusing—and how to fix it." Ashish explains how systemic misaligned incentives, opaque insurance practices, and weak enforcement drive up patient costs and mistrust in the health care system. He outlines the emotional and financial toll of surprise medical bills and argues for stronger accountability, technology-driven transparency, and shared responsibility across hospitals, insurers, providers, and patients. Ashish offers listeners practical takeaways, such as the role of digital tools in cost clarity, the need for enforcement that closes loopholes, and how patients can advocate for fairer, more predictable care. Our presenting sponsor is Microsoft Dragon Copilot. Microsoft Dragon Copilot, your AI assistant for clinical workflow, is transforming how clinicians work. Now you can streamline and customize documentation, surface information right at the point of care, and automate tasks with just a click. Part of Microsoft Cloud for Healthcare, Dragon Copilot offers an extensible AI workspace and a single, integrated platform to help unlock new levels of efficiency. Plus, it's backed by a proven track record and decades of clinical expertise, and it's built on a foundation of trust. It's time to ease your administrative burdens and stay focused on what matters most with Dragon Copilot, your AI assistant for clinical workflow. VISIT SPONSOR → https://aka.ms/kevinmd SUBSCRIBE TO THE PODCAST → https://www.kevinmd.com/podcast RECOMMENDED BY KEVINMD → https://www.kevinmd.com/recommended

Leaders often assume transformation comes from learning new skills or following the latest management trend. But real change begins when we confront our own beliefs, reflect deeply, and choose to step out of victimhood into agency. That inner work is what lays the foundation for lasting growth in how we lead and live. Only then can leaders create change that resonates far beyond the workplace.In this episode of the Happiness Squad Podcast, Ashish Kothari and Shawn Quinn talk about the deep reflection leaders need to build their own reality and move from victimhood to agency in life and leadership.Shawn Quinn is the Managing Partner of Lift Consulting and Faculty Director of the Positive Leadership program at the University of Michigan's Ross School of Business. A leading voice in positive leadership and organizational transformation, he has advised global companies including GE, Coca-Cola, American Express, and the U.S. Army. Shawn is also co-author of Leading Innovation: How to Jumpstart Your Organization's Growth Engine.Shawn and Ashish explored how transformation doesn't come from another training, another framework, or another leadership fad. It happens when we pause, reflect, and face the beliefs that hold us back.Things you will also learn in this episode:• Breaking free from a victim mindset• Why belief shifts matter more than skills in true transformation• The power of small experiments, reflection, and awareness to spark change• How leaders at any level—not just executives—can create meaningful impact• How workplace behaviors ripple outward into family, children, and community• The challenge of systems and people resisting changeTune in now and see for yourself how this shift unlocks the kind of transformation no trend or tactic can deliver.✅Resources:• Related episode: (Robert Quinn) https://player.captivate.fm/episode/1b7c5df6-06e1-4929-83d3-5849caa6b9b5 • Strengthsfinder by Gallup: https://www.gallup.com/cliftonstrengths/en/254033/strengthsfinder.aspx • A Fundamental State of Leadership Approach: https://scholar.valpo.edu/cgi/viewcontent.cgi?article=1444&context=jvbl • Charles Snyder's Hope Theory: https://www.mindtools.com/aov3izj/snyders-hope-theory • The Sunflower Model: https://player.captivate.fm/episode/ee784c9c-cf26-48df-b07f-b4c0dcc638f3 • The Sunflower Model: https://happinesssquad.com/the-sunflower-model-career-transition-guide-with-ashish-kothari/ • The Power of the 5:1 Ratio: https://michiganvirtual.org/blog/the-power-of-the-51-ratio-in-the-classroom-how-fostering-positive-interactions-can-transform-student-learning/ • Martin Seligman's Learned Helplessness:

Grow your management tools for opioid withdrawal in the hospital. Investigate how to decide between methadone and buprenorphine, additional medications to manage symptoms and how and when to use short-acting opioids for management of withdrawal. We're joined by Ashish Thakrar, MD at the University of Pennsylvania.  Claim CME for this episode at curbsiders.vcuhealth.org! By listening to this episode and completing CME, this can be used to count towards the new DEA 8-hr requirement on substance use disorders education. Episodes | Subscribe | Spotify | iTunes | CurbsidersAddictionMed@gmail.com | CME! Show Segments Intro, disclaimer, guest bio Guest one-liner Case from Kashlak; Definitions Symptoms of opioid withdrawal Medications for the management of opioid withdrawal Buprenorphine precipitated withdrawal Starting Buprenorphine: Experiences and Strategies  Titrating Methadone: Dosage and Adjuncts Adjunctive short-acting opioids Emerging Trends in Drug Supply: Xylazine and Medetomidine Outro  Credits Producer, Show Notes: Zina Huxley-Reicher Infographics: Zina Huxley-Reicher MD and Zoya Surani Hosts: Carolyn Chan, MD MHS, Zina Huxley-Reicher MD, Shawn Cohen, MD Reviewer: Payel Jhoom Roy, MD, MSc Showrunner: Carolyn Chan, MD, MHS Technical Production: PodPaste Guest: Ashish Thakrar, MD MHSP Sponsor: Mint Mobile  Shop plans at MINTMOBILE.com/CURB Sponsor: Freed Use code: CURB50 to get $50 off your first month when you subscribe! Sponsor: FIGS  We've teamed up with FIGS, and now Curbsiders listeners can get 15% off. Just go to WearFIGS.com and use code FIGSRX.

Welcome Online Family!  Join us in worshipping the King of Kings Jesus. If you have a need that we can pray for, please feel free to comment below or DM us and we would love pray with you! To support this ministry and help us continue to reach people all around the world click here: https://bit.ly/36vpxdD Subscribe to get notifications on all the latest sermons and worship covers, click on the bell icon to receive notifications every time we post! Share with your friends, colleagues, loved ones.  ------------------------------------------- Connect with us on all Commission Socials: https://linktr.ee/CommissionChurch

In this episode, Uzair talks to Ashish Pradhan about the revolution in Nepal and what comes next for the country. We focused on the underlying factors that led to the outburst of protests across the country, how the royalists tried to capture power, and what the priorities of the new interim prime minister are. We also talked about the role of foreign powers in the country, especially India and China. Ashish Pradhan is Senior Adviser to the President at International Crisis Group where he supports the president's highest priorities and helps execute special projects aligning with the organisation's strategic goals. Prior to this role, Ashish served as Crisis Group's Senior UN Analyst and represented the organization at the United Nations. He previously served as Crisis Group's Nepal expert, conducting research on the post-conflict peace process. Chapters: 0:00 Introduction 2:00 Structural issues in Nepal 14:30 Social media ban 22:30 Violence, army, and royalists 31:10 Sushila Karki's priorities 38:30 Elections and Gen-Z 45:00 Role of India and China

Is it time to say goodbye to your DSLR? Are mirrorless cameras really the future of dental photography? If your DSLR is still working perfectly, should you upgrade now or wait for the right time? Jaz is joined by Dr. Ashish Soneji in this game-changing episode to discuss the death of the DSLR and why the shift to mirrorless cameras is inevitable. They break down whether you should proactively switch or strategically hold off, plus what this means for your existing lenses. You'll also learn the rules of mix and match—can you use your current DSLR lens on a mirrorless body? And most importantly, which mirrorless lenses are worth buying and which ones to avoid (hint: if they don't have markings, you might be in trouble!). If you care about consistent, high-quality dental photography, this episode is a must-listen! https://youtu.be/Y29Mnz26ZIU Watch PDP239 on Youtube Protrusive Dental Pearl: Jaz introduces the 21-Day Photography Challenge for beginners, featuring 21 short videos to help dentists take clear, well-framed photos. In just three weeks, participants will master essential shots, including tricky occlusal views, at their own pace. Key Takeaways: Investing in quality equipment pays off in the long run. Mirrorless cameras offer significant advantages over DSLRs. Lighting is crucial for capturing quality images. Standardized images require barrel markings on lenses. Second-hand DSLRs can be a cost-effective option for beginners. The evolution of camera technology impacts photography practices. Choosing the right lens is essential for dental photography. Flash consistency is vital for accurate representation in images. Upgrading to mirrorless is a smart move for future-proofing photography. Upgrading your camera setup should align with your clinical progression. Mirrorless cameras are lighter and offer better image quality. Consider the size and transportability of your camera kit. Timing for upgrades can be linked to job changes or equipment failures. Image quality is influenced by megapixels, especially for presentations and printing. Using the right tools, like smaller mirrors and retractors, can improve photography outcomes. Testing second-hand cameras before purchase is crucial to avoid issues. Mobile photography is improving, but may not match the quality of dedicated cameras. Investing in good photographic equipment is essential for quality results. Highlights of this episode: 00:00 Teaser 00:47 Intro 01:41 Protrusive Dental Pearl 03:30 Ashish's Journey into Photography 09:06 The Shift from DSLR to Mirrorless Cameras 13:33 Choosing the Right Camera Setup 15:32 Upgrading to Mirrorless Cameras 19:22 Camera Recommendations for Beginners 27:23 Investing in Reliable Flash Equipment 32:20 Investing in Reliable Flash Equipment 33:48 When to Upgrade Your Camera Setup 38:08 Getting HQ Images: Mirrorless vs DSLR 42:03 Avoiding Newer Lenses 43:23 Posterior Quadrant Photography 47:50 Tips for Buying Second-Hand Cameras 49:54 Mobile Dental Photography: Are We There Yet? 53:20 Getting Your First Mirrorless Camera 55:40 Course Information 57:53 Outro

Soothe growing pains with a fractional COO New Livestream guest- Ashish Gupta I'm happy to have Ashish join me on a live broadcast. He's got operational experience in making things go smoothly across a great array of business sizes and types. Tune in and as we'll be discussing how a growing business can take advantage of a fractional Chief Operating Officer while controlling costs vs. having a full time expert on staff. This is a ‘must see event' for anyone growing quickly in their business or who knows they suffer from bottlenecks and clients who regularly ‘slip through the cracks' of how you would like them to be served. Be sure to join live so that you can ask questions, replay will be available. Set yourself a reminder on YouTube here: https://youtube.com/live/I9HhK21cdr0 We'll be going live September 08, 2025 1 PM Atlantic Time and 12 Noon Eastern Time See you there! David C Barnett **** - Join David's email list so you never miss any new videos or important information or insights, RECEIVE 7 FREE GIFTS!!- https://www.DavidCBarnettList.com **** Do Business with David using these incredible internet links... - David's Blog where you can find hundreds of free videos and articles, https://www.DavidCBarnett.com - Book a call with David and let him help you with your project, https://www.CallDavidBarnett.com - Learn how to buy a successful and profitable business in a risk-controlled way https://www.BusinessBuyerAdvantage.com - Get help selling your business, https://www.HowToSellMyOwnBusiness.com - Get better organized in your business, https://www.EasySmallBizSystems.com - Learn to make better cash flow forecasts and write incredibly effective business plans from scratch!, https://www.BizPlanSchool.com - Learn to build an equity asset with insurance! visit https://www.NewBankingSolution.com -Did you sign up for an expensive Merchant Cash Advance for your business and now struggle to make the payments? Find out how you can negotiate your way out at https://www.EndMyMCA.com

Political strategist and human rights activist Ashish Prashar joins Anthony Davis to discuss the fallout from Trump's random tariff reboot as allies are punished by nonsense trade deals. Plus Trumps threatens geopolitical fallout with Canada, UK and France as they join 147 nations recognizing a Palestinian state in the face of mass starvation - only on The Weekend Show. Support Our Sponsors: Shopify: Sign up for a one-dollar per month trial at https://shopify.com/weekend Join this channel for exclusive access and bonus content: https://www.youtube.com/channel/UCkbwLFZhawBqK2b9gW08z3g/join Five Minute News is an Evergreen Podcast, covering politics, inequality, health and climate - delivering independent, unbiased and essential news for the US and across the world. Visit us online at http://www.fiveminute.news Follow us on Bluesky https://bsky.app/profile/fiveminutenews.bsky.social Follow us on Instagram http://instagram.com/fiveminnews Support us on Patreon http://www.patreon.com/fiveminutenews You can subscribe to Five Minute News with your preferred podcast app, ask your smart speaker, or enable Five Minute News as your Amazon Alexa Flash Briefing skill. Please subscribe HERE https://www.youtube.com/channel/UCkbwLFZhawBqK2b9gW08z3g?sub_confirmation=1 CONTENT DISCLAIMER The views and opinions expressed on this channel are those of the guests and authors and do not necessarily reflect the official policy or position of Anthony Davis or Five Minute News LLC. Any content provided by our hosts, guests or authors are of their opinion and are not intended to malign any religion, ethnic group, club, organization, company, individual or anyone or anything, in line with the First Amendment right to free and protected speech. Learn more about your ad choices. Visit megaphone.fm/adchoices